Teva to Donate Potential COVID-19 Treatment, Hydroxychloroquine Sulfate Tablets to Hospitals Nationwide
March 19 2020 - 8:23PM
Business Wire
Teva will donate 6 Million tablets
through wholesalers to hospitals by March 31, and more than 10
Million within a month
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA)
announced today the immediate donation of more than 6 million doses
of hydroxychloroquine sulfate tablets through wholesalers to
hospitals across the U.S. to meet the urgent demand for the
medicine as an investigational target to treat COVID-19. The
company is also looking at additional ways to address the global
need.
“We are committed to helping to supply as many tablets as
possible as demand for this treatment accelerates at no cost,” said
Brendan O’Grady, Teva Executive Vice President, North America
Commercial. “Immediately upon learning of the potential benefit of
hyroxychloroquine, Teva began to assess supply and to urgently
acquire additional ingredients to make more product while arranging
for all of what we had to be distributed immediately.”
Additional production of hydroxychloroquine sulfate tablets is
also being assessed and subsequently ramped up with materials that
are being sent to Teva from our ingredient supplier. Teva will ship
6 Million tablets through wholesalers to hospitals by March 31, and
more than 10 Million within a month.
Hydroxychloroquine sulfate tablets manufactured by Teva are
approved by U.S. Food and Drug Administration (FDA) for the
treatment of malaria, lupus erythematosus and rheumatoid arthritis.
Although the product is not currently approved for use in the
treatment of COVID-19, it is currently under investigation for
efficacy against the coronavirus and has been requested by US
government officials to be made available for use immediately. The
Company is also reviewing supply of both hydroxychloroquine and
chloroquine globally to determine whether there are additional
supply and access opportunities for patients.
Teva is also actively looking across its expansive range of
products to determine if the company can help to provide any other
products that may be relevant in addressing acute and substantial
need during the COVID-19 crisis.
ABOUT TEVA
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has
been developing and producing medicines to improve people’s lives
for more than a century. We are a global leader in generic and
specialty medicines with a portfolio consisting of over 3,500
products in nearly every therapeutic area. Around 200 million
people around the world take a Teva medicine every day, and are
served by one of the largest and most complex supply chains in the
pharmaceutical industry. Along with our established presence in
generics, we have significant innovative research and operations
supporting our growing portfolio of specialty and biopharmaceutical
products. Learn more at www.tevapharm.com.
FORWARD LOOKING STATEMENT
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
which are based on management’s current beliefs and expectations
and are subject to substantial risks and uncertainties, both known
and unknown, that could cause our future results, performance or
achievements to differ significantly from that expressed or implied
by such forward-looking statements. Factors that could cause or
contribute to such differences are discussed in our Quarterly
Reports on Form 10-Q for the first, second and third quarter of
2019 and in our Annual Report on Form 10-K for the year ended
December 31, 2018, including in the sections captioned “Risk
Factors.” Forward-looking statements speak only as of the date on
which they are made, and we assume no obligation to update or
revise any forward-looking statements or other information
contained herein, whether as a result of new information, future
events or otherwise. You are cautioned not to put undue reliance on
these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200319005871/en/
IR Contacts United States Kevin C. Mannix (215) 591-8912
Israel Ran Meir 972 (3) 926-7516 PR Contacts
United States Kelley Dougherty 973-832-2810 Israel
Yonatan Beker 972 (54) 888 5898
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Apr 2023 to Apr 2024